Compare WAVE & KYNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WAVE | KYNB |
|---|---|---|
| Founded | 2011 | 1993 |
| Country | Israel | United States |
| Employees | N/A | 34 |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.4M | 27.6M |
| IPO Year | 2021 | N/A |
| Metric | WAVE | KYNB |
|---|---|---|
| Price | $7.98 | $7.00 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 23.3K | 7.4K |
| Earning Date | 05-07-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $436.84 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $0.15 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.52 | $6.32 |
| 52 Week High | $10.50 | $9.58 |
| Indicator | WAVE | KYNB |
|---|---|---|
| Relative Strength Index (RSI) | 41.05 | 55.93 |
| Support Level | $6.92 | $6.88 |
| Resistance Level | $8.60 | $7.41 |
| Average True Range (ATR) | 0.76 | 0.30 |
| MACD | -0.26 | 0.01 |
| Stochastic Oscillator | 8.36 | 35.00 |
Eco Wave Power Global AB is a Sweden-based wave energy company engaged in the development of a smart and cost-efficient WEC, technology that converts ocean and sea waves into clean electricity. Its WEC technology employs units of point absorber floating devices, referred to as floaters, which are installed on existing marine structures such as piers, breakwaters, and jetties, or in locations in which such marine structures are required. Geographical presence in Israel, USA and Mexico.
Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease. The company's research programs target cancer and rare disease indications, including anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) and metastatic castration-resistant prostate cancer (mCRPC). Itd pipeline drug candidates include Roxadustat and FG-3246.